Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Selegiline transdermal system: in the treatment of major depressive disorder.

Frampton JE, Plosker GL.

Drugs. 2007;67(2):257-65; discussion 266-7.

PMID:
17284087
3.

Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trial.

Feiger AD, Rickels K, Rynn MA, Zimbroff DL, Robinson DS.

J Clin Psychiatry. 2006 Sep;67(9):1354-61.

PMID:
17017821
4.

Transdermal selegiline: the new generation of monoamine oxidase inhibitors.

Patkar AA, Pae CU, Masand PS.

CNS Spectr. 2006 May;11(5):363-75. Review.

PMID:
16641841
6.

Transdermal selegiline.

Patkar AA, Pae CU, Zarzar M.

Drugs Today (Barc). 2007 Jun;43(6):361-77. Review.

PMID:
17612708
7.
8.

Selegiline transdermal system: a novel treatment option for major depressive disorder.

Nandagopal JJ, DelBello MP.

Expert Opin Pharmacother. 2009 Jul;10(10):1665-73. doi: 10.1517/14656560903048942. Review.

PMID:
19527191
9.

Predictors of relapse in patients with major depressive disorder in a 52-week, fixed dose, double blind, randomized trial of selegiline transdermal system (STS).

Jang S, Jung S, Pae C, Kimberly BP, Craig Nelson J, Patkar AA.

J Affect Disord. 2013 Dec;151(3):854-9. doi: 10.1016/j.jad.2013.07.023. Epub 2013 Aug 16.

PMID:
24021959
10.

Pressor response to tyramine after single 24-hour application of a selegiline transdermal system in healthy males.

Barrett JS, Hochadel TJ, Morales RJ, Rohatagi S, DeWitt KE, Watson SK, Darnow J, Azzaro AJ, DiSanto AR.

J Clin Pharmacol. 1997 Mar;37(3):238-47.

PMID:
9089426
11.

The selegiline transdermal system in major depressive disorder: a systematic review of safety and tolerability.

Robinson DS, Amsterdam JD.

J Affect Disord. 2008 Jan;105(1-3):15-23. Epub 2007 Jun 13. Review.

PMID:
17568687
12.

Transdermal selegiline (Emsam).

[No authors listed]

Med Lett Drugs Ther. 2006 May 22;48(1235):41-2. No abstract available.

PMID:
16770292
13.

Translating the evidence on atypical depression into clinical practice.

Hyman Rapaport M.

J Clin Psychiatry. 2007;68 Suppl 3:31-6. Review.

14.

A critical appraisal of the selegiline transdermal system for major depressive disorder.

Bied AM, Kim J, Schwartz TL.

Expert Rev Clin Pharmacol. 2015;8(6):673-81. doi: 10.1586/17512433.2016.1093416. Epub 2015 Oct 1. Review. Erratum in: Expert Rev Clin Pharmacol. 2016;9(2):339.

PMID:
26427518
15.

Transdermal selegiline and intravenous cocaine: safety and interactions.

Houtsmuller EJ, Notes LD, Newton T, van Sluis N, Chiang N, Elkashef A, Bigelow GE.

Psychopharmacology (Berl). 2004 Feb;172(1):31-40. Epub 2003 Nov 6.

PMID:
14605792
16.

Symptoms of sexual dysfunction in patients treated for major depressive disorder: a meta-analysis comparing selegiline transdermal system and placebo using a patient-rated scale.

Clayton AH, Campbell BJ, Favit A, Yang Y, Moonsammy G, Piontek CM, Amsterdam JD.

J Clin Psychiatry. 2007 Dec;68(12):1860-6.

PMID:
18162016
18.

Monoamine oxidase inhibitors: a new generation.

Robinson DS.

Psychopharmacol Bull. 2002 Summer;36(3):124-38.

PMID:
12473970
19.

MAO inhibitors: risks, benefits, and lore.

Wimbiscus M, Kostenko O, Malone D.

Cleve Clin J Med. 2010 Dec;77(12):859-82. doi: 10.3949/ccjm.77a.09103. Review.

PMID:
21147941
20.

Selegiline transdermal system in major depressive disorder: profile report.

Frampton JE, Plosker GL.

CNS Drugs. 2007;21(6):521-4. No abstract available.

PMID:
17521230

Supplemental Content

Support Center